Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma

Kongying Lin†, Qizhen Huang**, Lei Wang††, Jianxing Zeng†, Zongren Ding†, Hongzhi Liu†, Jun Fu†, Pengfei Guo*, Zhenwei Chen**, Yongyi Zeng†, Weiping Zhou** and Jingfeng Liu†,3*

1 Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China, 2 Department of Radiation Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China, 3 Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China, 4 The Big Data Institute of Southeast Hepatobiliary Health Information, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China, 5 The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

Background and Aims: The incidence of non-B, non-C hepatocellular carcinoma (NBNC-HCC) is increasing. Like in hepatitis B virus (HBC)/HCV-associated HCC, treatment of NBNC-HCC after resection is challenging due to its high recurrence rate. However, few studies on the recurrence of NBNC-HCC have been published in the past decades. Hence, we aimed to investigate the risk factors for recurrence of NBNC-HCC and construct pre- and postoperative prognostic models for predicting recurrence in these patients who underwent curative resection.

Methods: We retrospectively analyzed 608 patients who underwent liver resection for NBNC-HCC. A multivariate Cox proportional hazard regression analysis was conducted to identify the independent risk factors of recurrence, based on which the prediction nomogram models were constructed and validated. The predictive performance of the models was assessed using the concordance index, time-dependent receiver operating characteristic curve, prediction error cure, and calibration curve. To facilitate clinical use, we stratified the patients into three distinct risk groups based on the score of the models. The cutoff scores of the models were determined by a survival tree analysis.

Results: Multivariable analysis identified neutrophil-to-lymphocyte ratio, alpha fetoprotein, tumor number, and tumor diameter as independent preoperative risk factors for recurrence. In addition to these variables, microvascular invasion was an independent postoperative risk factor for recurrence. The pre- and postoperative nomograms were constructed based on these variables. The C-index of the pre- and postoperative nomograms was 0.689 and 0.702 in the training cohort, 0.682 and 0.688 in the validation cohort, respectively, which were both higher than those of the conventional Barcelona Clinic Liver Cancer (BCLO) and 8th edition of the American Joint Committee on Cancer (AJCC8th) staging systems. In addition, the pre- and postoperative nomograms...
INTRODUCTION

Hepatocellular carcinoma (HCC) is the fifth most common cancer and third leading cause of cancer-related deaths worldwide (1). Chronic infections with hepatitis B (HBV) and C viruses (HCV) are the prominent etiological factors for HCC. However, with the adoption of HBV immunization programs and control of HCV transmission, the incidence of HBV\HCV-associated HCC has decreased in recent years (2, 3). The number of patients with HCC who are seronegative for both HBV and HCV, so called “NBNC-HCC,” is gradually increasing (4, 5).

Due to the shortage of donor organs, surgical resection remains the main treatment strategy for patients with HCC who have a good liver function and resectable tumors (6). However, long-term survival after surgery remains unsatisfactory due to the high incidence of tumor recurrence (7). Owing to the heterogeneity of HCC, some highly selected patients may benefit from a prognostic prediction model, well-selected therapeutic assignment, and strict postoperative monitoring (8, 9). There are several studies on constructed prognostic models for HCC; however, very few studies have specifically focused on the recurrence of patients with NBNC-HCC. Considering the different clinical manifestations and prognostic outcomes of NBNC-HCC and viral-associated HCC, the study of its risk factors and establishment of prognostic models may provide important insight into novel strategies for the treatment and postoperative monitoring of NBNC-HCC.

Host inflammatory response to cancer and tumor-mediated systemic inflammation promote migration, invasion, and metastasis of malignant cells (10, 11); they are prognostic factors for HCC (12). Recent studies have demonstrated that preoperative inflammatory indices, such as the neutrophil-to-lymphocyte ratio (NLR) (13), neutrophil times γ-glutamyl transpeptidase-to-lymphocyte ratio (NγTLR) (14), platelet-to-lymphocyte ratio (PLR) (15), prognostic nutritional index (PNI) (16), aspartate aminotransferase-to-neutrophil ratio (ANRI) (17), γ-glutamyl transpeptidase-to-platelet ratio (GPR) (18), aspartate aminotransferase-to-lymphocyte ratio index (ALRI) (19) and platelet times neutrophil-to-lymphocyte ratio (PNLR) (20) are independent prognostic factors for patients with HCC who have undergone liver resection and have been used in the construction of several prognosis prediction models; however, the relationship between these inflammatory indexes and prognosis of NBNC-HCC, and the inflammatory index with the highest prognostic significance remain unclear.

In our study, we aimed to: (1) investigate the relationship between inflammatory indexes and recurrence of NBNC-HCC, (2) investigate the pre- and postoperative risk factors for recurrence of NBNC-HCC, and (3) construct a pre- and postoperative nomogram model for the prediction of recurrence of NBNC-HCC.

MATERIALS AND METHODS

Patients

Data from patients diagnosed with NBNC-HCC who underwent hepatectomy as a primary anti-cancer therapy between April 28, 2008 and December 30, 2015 were extracted from the primary liver cancer big data (PLCBD) (21, 22). In this study, patients with HCC who were seronegative for hepatitis B surface antigen, HBV-deoxyribonucleic acid (DNA), hepatitis C antibody, and HCV-RNA test were considered patients with NBNC-HCC (23).

All data in this study were verified by three independent researchers, and the study was approved by the institutional ethics committee of Mengchao Hepatobiliary Hospital of Fujian Medial University.

Patients with Child Pugh A or B7 liver function, no extrahepatic metastasis, no macroscopic vascular invasion, and who underwent R0 resection (complete removal of all detectable tumor nodes with tumor-free margins confirmed by histological examination) were included. Patients who underwent palliative tumor resection or any preoperative anti-HCC therapy, with a history of other cancers, or incomplete clinical data were excluded.

Preoperative Assessment, Hepatectomy, and Follow-Up

All patients underwent routine preoperative examinations, which included hepatitis B and C immunology, HBV-DNA

Abbreviations: NBNC-HCC, Non-B non-C hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease; ALD, alcoholic liver disease; BCLC, Barcelona Clinic Liver Cancer staging system; HBcAb, hepatitis B virus core antibody; RBCs, red blood cells; WBCs, white blood cells; Hb, hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index; ANRI, aspartate aminotransferase to neutrophil ratio index; ALRI, aspartate aminotransferase to lymphocyte ratio index; PNLR, platelet times neutrophil to lymphocyte ratio; NγTLR, derived neutrophil to lymphocyte ratio; GLR, glutamyl transpeptidase to platelet ratio; NγPLR, derived neutrophil to lymphocyte ratio; AFP, alpha fetoprotein; MVI, microvascular invasion.

Conclusions: We constructed pre- and postoperative prognostic models for predicting recurrence in patients with NBNC-HCC who underwent curative resection. They can play a supplementary role to the traditional staging system.

Keywords: non-B non-C hepatocellular carcinoma, resection, recurrence, inflammation, nomogram
load, alpha-fetoprotein (AFP) levels, liver and kidney function examinations, chest radiography, abdominal ultrasonography, contrast-enhanced computed tomography, and magnetic resonance imaging. HCC was diagnosed according to the practice guidelines recommended by the American Association for the Study of Liver Diseases (24). The choice of performing anatomical or partial hepatectomy is commonly based on the patient’s liver function status, tumor number, and location. In simple terms, anatomical hepatectomy was preferentially performed for patients with a good liver function and tumors located within a segment, sector, and hemiliver. Partial hepatectomy was performed for tumors that were peripherally located or patients with unsatisfactory liver function. Intraoperative liver ultrasonography was routinely used to ensure that all detectable tumors were completely removed. The follow-up of patients after discharge was performed in the outpatient clinic. The follow-up program and diagnostic criteria for tumor recurrence are reported in a previous study (9).

Clinicopathologic Variables

For hematological investigations, we used the results of the most recent test that was performed within 15 days prior to surgery. The formulae of the indices (NLR, PLR, GPR, PNLR, ANRI, ALRI, DNLR, and NyLR) are reported in a previous study (14, 18, 25–27). The preoperative imaging data, including tumor number and diameter was obtained from contrast-enhanced Computed Tomography or contrast-enhanced magnetic resonance imaging. Tumor diameter was the diameter of the largest tumor. Histologic grading of the tumor was done according to the Edmondson-Steiner classification. The definition of microvascular invasion (MVI) from a previous study (28). The pathological review of all resected specimens was carried out independently by two pathologists.

Statistical Analysis

Categorical variables were expressed as number (percentage) and compared using the χ2 test or Fisher’s exact test. Continuous variables were expressed as mean (standard deviation SD) and compared using the Student t test or the Mann–Whitney U test. Univariate and multivariate Cox proportional hazard regression analyses were performed to determine the independent prognostic factors for recurrence. Clinical variables considered to be potentially relevant (p<0.05 in univariate analyses) were entered in the multivariate Cox proportional hazard regression analyses, and the final independent risk factors for recurrence were identified by the multivariable analyses with stepwise backward selection method.

The nomograms were constructed based on the results of multivariable analyses of recurrence in the training cohort. The R code used for construction of nomogram was shown in the supporting information. The preoperative nomogram was developed on the available preoperative clinicopathologic data. The postoperative nomogram was based on all available clinicopathologic variables. The predictive performance of the nomograms was measured using Harrell’s concordance index (C-index), time-dependent areas under the receiver operating characteristic curve (tDAUC), prediction error curve, and calibration plot (29, 30). The cutoff of models was determined by a survival tree analysis (29). The cumulative recurrence between each risk group was assessed and tested using Kaplan-Meier curves and the log-rank test, respectively. All statistical tests were two-tailed, and P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 20.0 and R version 3.0 (http://www.r-project.org/); the R packages of “table1,” “rms,” “CsChange,” “survminer,” “survival,” “pec,” “riskRegression,” “timeROC,” and “party” were used.

RESULTS

Patients’ Characteristics

A total of 608 eligible patients were included in the study. They were randomly divided into a training cohort (n=456) and validation cohort (n=152) in a 3:1 ratio. A comparison of the clinicopathologic characteristics between the two cohorts is shown in Table 1. There were no significant differences in the clinicopathologic features between the two cohorts. The mean age was 59.2 ± 11.2 years and 58.3 ± 11.7 years in the training and validation cohorts, respectively. Most of the patients were male (85.5–87.5%), and few patients had cirrhotic livers (32.9–35.5%). The mean tumor diameter was 7.06 ± 3.99 cm and 6.80 ± 4.12 cm in the training and validation cohorts, respectively. Most of the patients harbored solitary tumors (86.2–83.6%).

POSTOPERATIVE PROGNOSIS

The median follow-up period was 44.3 (range, 2.1–114.7) months and 45.3 months (range, 1.9–114.7) months in the training cohort and validation cohort, respectively. In the training cohort, the postoperative 1-, 3-, and 5-year overall survival (OS) rates were 91.7, 72.8, and 57.4%, respectively, and the corresponding cumulative recurrence rates were 24.2, 37.5, and 48.6%, respectively. In the validation cohort, the postoperative 1-, 3-, and 5-year OS rates were 87.2, 67.7, and 54.5%, respectively, and the corresponding cumulative recurrence rates were 28.8, 43.3, and 48.0%, respectively.

Construction of Pre- and Postoperative Nomograms for Prediction of Recurrence

All the variables shown in Table 1 were included in the univariate and multivariate Cox proportional hazard regression analyses to identify independent risk factors for recurrence. Results of the univariate analysis are shown in Table 2. On univariate analysis, there was a significant relationship between six inflammatory indexes (NLR, PLR, ALRI, PNLR, NyLR, and DNLR) and recurrence. Other significant variables were neutrophil count, lymphocyte count, aspartate aminotransferase, AFP, tumor diameter, tumor number, MVI, and satellite nodules.

To construct the preoperative model, presence of MVI and satellite nodules, which were recorded only postoperatively, were
Baseline clinical characteristics of patients.

|                          | Training cohort (n=456) | Validation cohort (n=152) | P-value |
|--------------------------|-------------------------|---------------------------|---------|
| **Age, Mean (SD), years**| 59.2 (11.2)             | 58.3 (11.7)               | 0.402   |
| **Gender**               |                         |                           |         |
| Female                   | 66 (14.5%)              | 19 (12.5%)                | 0.636   |
| Male                     | 390 (85.5%)             | 133 (87.5%)               |         |
| **Alcohol consumption**  |                         |                           |         |
| No                       | 321 (70.4%)             | 113 (74.3%)               | 0.407   |
| Yes                      | 135 (29.6%)             | 39 (25.7%)                |         |
| **Cigarette smoking**    |                         |                           |         |
| No                       | 278 (61.0%)             | 106 (69.7%)               | 0.065   |
| Yes                      | 178 (39.0%)             | 46 (30.3%)                |         |
| **Hypertension**         |                         |                           | 0.959   |
| Absent                   | 321 (70.4%)             | 108 (71.1%)               |         |
| Present                  | 135 (29.6%)             | 44 (28.9%)                |         |
| **Diabetes**             |                         |                           | 0.126   |
| Absent                   | 389 (85.3%)             | 121 (79.6%)               |         |
| Present                  | 67 (14.7%)              | 31 (20.4%)                |         |
| **Fatty liver**          |                         |                           | 0.501   |
| Absent                   | 403 (88.4%)             | 138 (90.8%)               |         |
| Present                  | 53 (11.6%)              | 14 (9.2%)                 |         |
| **Cirrhosis**            |                         |                           | 0.620   |
| Absent                   | 306 (67.1%)             | 98 (64.5%)                |         |
| Present                  | 150 (32.9%)             | 54 (35.5%)                |         |
| **BCLC staging system**  |                         |                           | 0.684   |
| 0                        | 9 (2.0%)                | 3 (2.0%)                  |         |
| A                        | 396 (86.8%)             | 128 (84.2%)               |         |
| B                        | 51 (11.2%)              | 21 (13.8%)                |         |
| **AJCC staging system**  |                         |                           | 0.961   |
| IA                       | 9 (2.0%)                | 3 (2.0%)                  |         |
| IB                       | 295 (64.7%)             | 96 (63.2%)                |         |
| II                       | 105 (23.0%)             | 35 (23.0%)                |         |
| IIIa                     | 47 (10.3%)              | 18 (11.8%)                |         |
| **HbcAb**                |                         |                           | 0.370   |
| Negative                 | 57 (12.5%)              | 24 (15.8%)                |         |
| Positive                 | 399 (87.5%)             | 128 (84.2%)               |         |
| **WBCs, Mean (SD), 10^9/L** | 5.85 (1.92)           | 5.67 (1.85)               | 0.320   |
| **RBCs, Mean (SD), 10^12/L** | 4.55 (0.57)          | 4.52 (0.53)               | 0.559   |
| **Hb, Mean (SD), g/L**   | 138.27 (17.47)          | 136.80 (16.15)            | 0.343   |
| **Neutrophil Count, Mean (SD), 10^9/L** | 3.68 (1.62)       | 3.53 (1.48)               | 0.305   |
| **Lymphocyte Count, Mean (SD), 10^9/L** | 1.66 (0.61)       | 1.64 (0.61)               | 0.640   |
| **Platelets, Mean (SD), 10^12/L** | 194.37 (75.32)  | 194.86 (85.53)            | 0.951   |
| **Total bilirubin, Mean (SD), umol/L** | 13.4 (5.29)      | 13.2 (5.10)               | 0.604   |
| **Albumin, Mean (SD), g/L** | 42.7 (3.71)        | 42.1 (3.60)               | 0.069   |
| **ALT, Mean (SD), U/L**  | 31.1 (24.9)             | 29.7 (24.6)               | 0.538   |
| **AST, Mean (SD), U/L**  | 34.0 (27.0)             | 30.7 (26.1)               | 0.186   |
| **GGT, Mean (SD), U/L**  | 76.3 (111)              | 89.7 (169)                | 0.360   |
| **NLR**                  | 2.47 (1.43)             | 2.36 (1.18)               | 0.371   |
| **PLR**                  | 127.27 (59.35)          | 127.87 (59.36)            | 0.914   |
| **PNI**                  | 51.00 (5.31)            | 50.24 (5.24)              | 0.127   |
| **ANRI**                 | 10.63 (9.47)            | 9.99 (8.50)               | 0.436   |
| **ALRI**                 | 23.89 (22.33)           | 21.53 (17.55)             | 0.182   |
| **PNLNR**                | 491.55                  | 471.33 (360.71)           | 0.567   |
| **GPR**                  | (419.79)                |                           |         |
| **NfNR**                 | 0.887 (1.43)            | 1.170 (2.79)              | 0.232   |
| **DNLR**                 | (341.11)                |                           |         |
| **AFN, ng/ml**           | 1.76 (1.44)             | 1.75 (0.75)               | 0.482   |
| <20                      | 236 (51.8%)             | 73 (48.0%)                |         |
| >20                      | 220 (48.2%)             | 79 (52.0%)                |         |

(Continued)
TABLE 2 | Univariate Cox regression analysis of risk factors of Recurrence in the training cohort.

| Variable                                  | B     | SE    | HR(95%CI)          | P-value |
|-------------------------------------------|-------|-------|--------------------|---------|
| Age, years                                | −0.003 | 0.006 | 0.997(0.985–1.009) | 0.609   |
| Gender, Male versus Female                | −0.040 | 0.020 | 0.961(0.963–1.438) | 0.846   |
| Alcohol consumption, Yes versus No        | 0.084  | 0.159 | 1.088(0.797–1.485) | 0.596   |
| Cigarette smoking, Yes versus No          | 0.054  | 0.148 | 1.059(0.789–1.412) | 0.716   |
| Hypertension, present versus absent        | 0.070  | 0.157 | 1.072(0.789–1.458) | 0.657   |
| Diabetes, present versus absent            | 0.004  | 0.205 | 1.004(0.672–1.508) | 0.984   |
| Fatty liver, present versus absent         | −0.234 | 0.242 | 0.791(0.492–1.272) | 0.333   |
| Cirrhosis, present versus absent           | 0.172  | 0.151 | 1.188(0.883–1.598) | 0.255   |
| HbAb, Present versus Negative              | 0.127  | 0.227 | 1.136(0.727–1.774) | 0.576   |
| WBCs, 10⁹/L                                | 0.059  | 0.033 | 1.060(0.994–1.131) | 0.074   |
| RBCs, 10⁹/L                               | 0.074  | 0.128 | 1.076(0.837–1.384) | 0.566   |
| Hgb, g/L                                   | −0.003 | 0.004 | 0.997(0.989–1.005) | 0.450   |
| Neutrophil count, 10⁹/L                    | 0.104  | 0.031 | 1.110(1.044–1.180) | 0.001   |
| Lymphocyte count, 10⁹/L                    | −0.322 | 0.127 | 0.725(0.565–0.930) | 0.011   |
| Platelets, 10⁹/L                           | 0.001  | 0.001 | 1.001(0.999–1.003) | 0.387   |
| Total bilirubin, umol/L                    | 0.003  | 0.014 | 1.000(0.976–1.031) | 0.835   |
| Albumin, g/L                               | 0.004  | 0.020 | 1.004(0.966–1.043) | 0.850   |
| ALT, U/L                                   | 0.002  | 0.003 | 1.002(0.997–1.007) | 0.426   |
| AST, U/L                                   | 0.004  | 0.002 | 1.004(1.001–1.008) | 0.025   |
| GGT, U/L                                   | 0.001  | 0.001 | 1.001(0.999–1.002) | 0.329   |
| NLR                                        | 0.187  | 0.038 | 1.206(1.120–1.299) | <0.001  |
| PLR                                        | 0.003  | 0.001 | 1.003(1.001–1.005) | 0.002   |
| PNI                                        | −0.018 | 0.014 | 0.982(0.956–1.009) | 0.187   |
| ANR                                        | 0.007  | 0.006 | 1.007(0.994–1.019) | 0.288   |
| ALRI                                       | 0.007  | 0.002 | 1.007(1.002–1.012) | 0.006   |
| PNLR                                       | 0.0004 | 0.0001 | 1.0004(1.0001–1.001) | <0.001   |
| GPR                                        | 0.043  | 0.048 | 1.044(0.950–1.147) | 0.372   |
| NyLr                                       | 0.001  | 0.0001 | 1.001(1.000–1.001) | <0.001  |
| DNLR                                       | 0.176  | 0.071 | 1.193(1.037–1.372) | 0.014   |
| AFP, ng/ml, >20 versus ≤20                 | 0.444  | 0.146 | 1.558(1.171–2.074) | 0.002   |
| Intraoperative blood transfusion, Yes versus No | 0.374 | 0.219 | 1.454(0.947–2.234) | 0.087   |
| Tumor size*, cm                           | 0.089  | 0.017 | 1.092(1.057–1.130) | <0.001  |
| Tumor number*, Multiple versus Solitary    | 1.301  | 0.172 | 3.673(2.623–5.145) | <0.001  |
| Tumor size, cm                            | 0.088  | 0.016 | 1.091(1.057–1.127) | <0.001  |
| Tumor number, Multiple versus Solitary     | 1.274  | 0.169 | 3.576(2.566–4.983) | <0.001  |
| MVI, Present versus Absent                | 0.726  | 0.153 | 2.067(1.531–2.792) | <0.001  |
| Satellite nodules, Present versus Absent   | 0.746  | 0.147 | 2.109(1.582–2.811) | <0.001  |
| Tumor capsule                              | Complete | Ref | Ref | Ref | 0.345 |
|                                           | Incomplete | 0.200 | 0.194 | 1.221(0.835–1.785) | 0.303   |
|                                           | None       | 0.332 | 0.228 | 1.394(0.891–2.179) | 0.146   |
|                                           | Edmondson-Steiner grading, III versus III/IV | 0.310 | 0.190 | 1.383(0.940–1.977) | 0.102   |

HbAb: hepatitis B virus core antibody; RBCs: red blood cells; WBCs: white blood cells; Hb: hemoglobin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; NLR: neutrophil to lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; PNLR: prognostic nutritional index; ANR: AST to neutrophil ratio index; ALRI: AST to Lymphocyte ratio index; PNLR, platelet-neutrophil-lymphocyte ratio; GPR: gamma-glutamyl transpeptidase (GGT) to platelet ratio; NyLr: neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio; DNLR, derived neutrophil to lymphocyte ratio; AFP, alpha fetoprotein; MVI, microvascular invasion; B, coefficient; SE, stand error; CI, confidence interval; HR, hazard ratio.

*Preoperative images were obtained from contrast-enhanced Computed Tomography or contrast-enhanced magnetic resonance imaging.

Performance of the Pre- and Postoperative Nomograms in Recurrence Prediction

In the training and validation cohorts, both nomograms had a satisfactory performance in recurrence prediction. The C-index of the preoperative nomogram in the training and validation cohorts was 0.689 (95% CI, 0.651–0.728) and 0.682 (0.618–0.746), respectively, which were significantly higher than the currently used Barcelona Clinic Liver Cancer (BCLC) staging system (0.593 [0.564–0.622], p<0.001; 0.593 [0.544–0.641], p=0.001) and 8th edition of the American Joint Committee on Cancer (AJCC) staging system [0.645 (0.608–0.682), p=0.018; 0.624 (0.562–0.687), p=0.024]. For the postoperative nomogram model, the C-index values were 0.702 (0.664–0.739) in the training cohort and 0.688 (0.622–0.753) in the validation cohort, which were greater than those of the BCLC (p<0.001, p=0.001, respectively) and 8th edition of the AJCC (p<0.001, p=0.002, respectively) staging systems.

Time-dependent receiver operating characteristic curve analysis was also performed to assess the discriminative performance of the nomograms. For the preoperative nomogram model, the median tAUCCs for prediction of 1-, 2-, and 3 year recurrences were 0.725 (range, 0.706–0.749) in the...
training cohort and 0.741 (0.677–0.743) in the validation cohort. For the postoperative nomogram model, the corresponding tdAUC was 0.751 (range, 0.722–0.753) in the training cohort and 0.755 (range, 0.687–0.768) in the validation cohort. Both models had higher tdAUCs than those of the BCLC and AJCC staging systems (Figures 2A, B). In addition, the prediction error curve analysis was used to assess the overall performance of the models. The nomogram models had a lower prediction error rate than the conventional staging systems (Figures 2C, D).

The calibration plots also displayed a good agreement between predictions of the pre- and postoperative nomogram models and the probability of 1-, 2-, and 3-year recurrence in the training and validation cohorts (Figure 3).

### Risk Stratification Based on the Nomograms’ Score

Each patient received an individualized risk score according to the individual scores calculated with the nomograms. We performed a survival tree analysis to determine the cutoff points of the risk score (Figure 4). Based on the cutoff points, the patients were stratified into three different risk subgroups (low-risk, intermediate-risk, and high-risk). The Kaplan-Meier analysis showed that the recurrence curves were widely separated among the three different risk groups in the training and validation cohorts, which further indicated that the nomograms had good discrimination ability for recurrence (Figure 5).

| Variable | B (SE) | HR (95% CI) | P-value |
|----------|--------|-------------|---------|
| Tumor number*, Multiple versus Solitary | 1.218 (0.175) | 3.381 (2.401–4.761) | <0.001 |
| Tumor size*, cm | 0.069 (0.018) | 1.072 (1.035–1.111) | <0.001 |
| AFP, ng/ml, >20 versus ≤20 | 0.485 (0.147) | 1.624 (1.219–2.166) | 0.001 |
| NLR | 0.132 (0.045) | 1.141 (1.048–1.246) | 0.003 |

NLR, neutrophil to lymphocyte ratio; AFP, alpha fetoprotein; B, coefficient; SE, standard error; CI, confidence interval; HR, hazard ratio.

| Variable | B (SE) | HR (95% CI) | P-value |
|----------|--------|-------------|---------|
| Tumor number, Multiple versus Solitary | 1.159 (0.173) | 3.187 (2.273–4.470) | <0.001 |
| Tumor size, cm | 0.066 (0.017) | 1.069 (1.033–1.106) | <0.001 |
| MVI, Present versus Absent | 0.462 (0.163) | 1.587 (1.153–2.186) | 0.005 |
| AFP, ng/ml, >20 versus ≤20 | 0.357 (0.154) | 1.428 (1.057–1.930) | 0.02 |
| NLR | 0.135 (0.045) | 1.144 (1.048–1.250) | 0.003 |

NLR, neutrophil to lymphocyte ratio; AFP, alpha fetoprotein; MVI, microvascular invasion; B, coefficient; SE, standard error; CI, confidence interval; HR, hazard ratio.

#### Figure 1
- Nomogram for preoperative prediction (A) and postoperative prediction (B) of Recurrence for NBNCHCC patients who underwent hepatectomy.
In addition, we combined the models with the BCLC/AJCC8th staging system and found that the models had a good re-stratification effect on the traditional staging systems. Because there were only 12 patients with BCLC stage 0 and AJCC stage IA tumors, these patients were incorporated into the group of patients with BCLC stage A or AJCC 8th stage IB. As shown in Figure 6, both models could re-stratify the patients with different recurrence risks in BCLC stages 0/A (p<0.001, preoperative nomogram model; p<0.001, postoperative nomogram model) well. The re-stratification ability of the models persisted in patients with BCLC B stage (p=0.044, preoperative nomogram model; p=0.037, postoperative nomogram model), but given that only a small number of patients were in the high-risk group, the re-stratification ability of models in patients with BCLC B stage needed be validated in a further large sample cohort. For the AJCC8th staging system, we found that the models distinguished patients with stages IA/IB (p<0.001, preoperative nomogram model; p<0.001, postoperative nomogram model), and II (p<0.001, preoperative nomogram model; p=0.002, postoperative nomogram model) well (Figure 7).

DISCUSSION

In this study, we reported significant independent risk factors for recurrence of NBNC-HCC, which included large tumor diameter, multiple tumor number, elevated AFP levels, elevated NLR, and presence of MVI. We also constructed pre- and postoperative nomograms for individualized prediction of recurrence in patients with NBNC-HCC who underwent curative resection. Both nomograms had a better predictive performance than the currently used BCLC and AJCC8th staging systems. Additionally, according to the individualized scores assessed using the nomograms, patients in cohorts can be stratified into three risk groups. These two easy-to-apply graphical models will be valuable in preoperative treatment planning, adjuvant therapy implementation, postoperative monitoring, and designing of clinical trials based on prognostic stratification.

Tumor diameter and number are important prognostic factors in the BCLC staging system; however, these tumor factors are insufficient to reflect the malignant characteristics
FIGURE 3 | The calibration curves for predicting the 1, 2, and 3-year Recurrence by the Pre- and postoperative nomogram in the training (A, B) and validation cohorts (C, D).

FIGURE 4 | Survival tree analysis of best cut-off scores in the training cohort. (A) postoperative nomogram model; (B) preoperative nomogram model.
of HCC (32). Compared to the BCLC staging system, the AJCC\textsuperscript{8th} staging system included the presence of MVI as a stratification criterion; however, given that MVI is a pathological feature that can only be diagnosed after surgery, it limits the applicability of this system in preoperative clinical decision making. Moreover, both the BCLC and AJCC\textsuperscript{8th} staging systems were not developed specifically for the prediction of HCC recurrence. The nomograms in this study integrated the independent risk factors for recurrence of NBNC-HCC, including the above three tumor-associated factors; serum tumor biomarker, AFP; and inflammatory index, NLR; thus, making them more accurate recurrence predictors.

Our recurrence nomograms were able to re-stratify patients in the same traditional staging system stages, and thus can play a supplementary role to the traditional staging system. The preoperative nomogram in this study, which had a significantly better predictive performance than the BCLC staging system, may be an additional tool for surgeons to identify high-risk patients before operation; thus, it may be valuable in preoperative treatment planning [e.g., preoperative transarterial chemoembolization (TACE), widened surgical margin]. Owing to the lack of consensus on follow-up procedures for the postoperative diagnosis of recurrence of HCC (33), using the postoperative nomogram can help surgeons to design stricter follow-up procedures (e.g., reduced interval of follow-up and more high-end imaging tests) and postoperative adjuvant therapy for the high-recurrence risk patients. For the current results, it is difficult to specify which model is better for the recurrence prediction. In terms of the predictive performance of the models, the C-index and t\textsuperscript{AUC} of the postoperative model were higher than those of the preoperative model, and the prediction error curve also shows that the postoperative model is better than the preoperative model, although the difference was not obvious, the postoperative model may be superior to the preoperative model considering that the postoperative model includes the indicator of MVI, MVI is currently widely recognized as an independent risk factor for recurrence in HCC. However, when the preoperative model shows poor prognosis of patients and the postoperative model...
shows good prognosis, it may more proper to choose the preoperative model. After all, the cost of shortening the follow-up interval is much less than the cost of finding recurrence of HCC too late. Further prospective studies may be needed to distinguish which model has better predictive power.

In addition, we included an inflammatory index in this study. To the best of our knowledge, this is the first study to investigate the association between a system inflammatory index and recurrence in NBNC-HCC. In this study, we analyzed nine inflammatory indices and found that the NLR was an independent risk factor for recurrence in NBNC-HCC. High NLR has been reported to be a poor prognostic factor for recurrence and OS in several malignancies, including HCC (13, 34). Given that NLR consists of serum neutrophil count and lymphocyte count, elevation of NLR can be reviewed as elevated neutrophil and lymphocyte counts. Neutrophilia can promote cancer cell growth and progression by releasing angiogenic factors and inflammatory mediators (28, 35, 36). On the other hand, lymphocytes play an anti-cancer role in host immunity by inducing cytotoxicity and inhibiting proliferation, invasion, and migration of cancer cells; lymphopenia may weaken this anti-cancer effect (37–39). All these factors included in the NLR were adverse factors for HCC, which could possibly explain why NLR could be used to evaluate the recurrence probability of patients with HCC. However, the mechanism underlying the association between NLR and recurrence of NBNC-HCC remains unclear and needs further elucidation.

This study had some limitations. First, it was limited by its retrospective nature and limited sample size; thus, selection bias was unavoidable. A large sample, outer validation cohort, and prospective study are needed to validate the nomograms in future. Second, postoperative adjuvant therapy information, such as postoperative adjuvant TACE (PA-TACE), has not been included in our study. Given that PA-TACE may improve the prognostic outcome of high-risk patients (40, 41), whether high-risk patients assessed by these nomograms can benefit from PA-TACE is to be determined. Third, the prognostic value of postoperative inflammatory indexes or the changed indexes after post-operation compared to pre-operation in HCC have been recognized in some studies, but this study did not include because the data of some postoperative inflammatory
indexes were missing. Last, the nomograms were generated using data of patients who underwent radical resection, which may not be applicable for patients receiving other therapies.

**CONCLUSION**

In summary, we developed pre- and postoperative nomograms for predicting the recurrence of patients with NBNC-HCC after resection. These two easy-to-apply graphical models will be valuable in guiding preoperative treatment planning, adjuvant treatment implementation, and postoperative monitoring for patients with NBNC-HCC.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**AUTHOR CONTRIBUTIONS**

KL, QH, LW, WZ, and JL: study conception, design, quality control of this study, drafting of the manuscript, and statistical analysis. JZ, ZD, HL, JF, PG, and ZC: data acquisition and data interpretation. YZ, WZ, and JL: resource and study supervision. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by Science and Technology project of Fuzhou (Grant number: 2019-SZ-49), Key Clinical Specialty Discipline Construction Program of Fuzhou, Fujian, P.R.C (Grant number: 201912002) and Fujian Provincial medical center of hepatobiliary.

**ACKNOWLEDGMENTS**

We thank our colleagues and all the patients who participated in this study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.612588/full#supplementary-material
REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. 2012. CA: Cancer J Clin (2015) 65(2):87–108. doi: 10.3322/caac.21262

2. Bosetti C, Levi F, Bioffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatol (Baltimore Md) (2008) 48(1):137–45. doi: 10.1002/hep.22312

3. Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol (2015) 29(6):919–28. doi: 10.1016/j.bpg.2015.09.007

4. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg (2015) 261(3):513–20. doi: 10.1097/SLA.0000000000000821

5. Nishiwha K, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Int J Oncol (2013) 43(5):1333–42. doi: 10.3892/ijo.2013.2061

6. Zhang X, Li C, Wen T, Yan L, Li B, Yang J, et al. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern. Eur J Gastroenterol Hepatol (2015) 27(8):933–40. doi: 10.1097/MEG.0000000000000383

7. Dhir V, Melia R, Douzeni J, Lin C, Zhen WK, Hussain SM, et al. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg (2016) 263(6):1112–25. doi: 10.1097/SLA.0000000000015556

8. Zhu SL, Chen J, Li H, Li LZ, Zhong JH. Efficacy of hepatic resection for huge (>10 cm) hepatocellular carcinoma: good prognosis associated with the uninnodal subtype. Int J Clin Exp Med (2015) 8(11):20581–8.

9. Yang P, Qiu J, Li J, Wu D, Wan X, Lau WY, et al. Nomograms for Pre- and Postoperative Survival of Patients With Undergoing Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg (2016) 263(4):778–86. doi: 10.1097/SLA.0000000000011339

10. Mantovani A, Allali P, Sica A, Ballow F. Cancer-related inflammation. Nature (2008) 454(7203):436–44. doi: 10.1038/nature07025

11. Ballow F, Mantovani A. Inflammation and cancer: back to Virchow! Lancet (London Engl) (2001) 357(9255):539–45. doi: 10.1016/S0140-6736(00)04046-0

12. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res (2014) 20(23):6212–22. doi: 10.1158/1058-8241.CCR-14-0442

13. Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, et al. Prognostic significance of neutrophil to lymphocyte ratio as a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg Oncol (2013) 20(2):301–5. doi: 10.1245/s10434-012-2516-z

14. Lin et al. Models for Recurrence in NBNC-HCC

15. Yang Z, Zhang J, Lu Y, Xu Q, Tang B, Wang Q, et al. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Oncotarget (2015) 6(40):43090–8. doi: 10.18632/oncotarget.5719

16. Wang L, Lin N, Lin K, Xiao C, Wang R, Chen J, et al. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. J Gastrointest Surg (2020) 10.1007/s11665-020-04588-5

17. Wang L, Lin N, Lin K, Xiao C, Wang R, Chen J, et al. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. J Gastrointest Surg Off J Soc Aliment Surg (2020). doi: 10.1007/s11665-020-04588-5

18. Huang Q, Lin K, Wang L, Zeng J, Liu H, Ding Z, et al. Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Propensity-Score Matching Study. Cancer Manage Res (2020) 12:9183–95. doi: 10.2147/CMAR.S270467

19. Usunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, et al. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Ann Surg (2014) 259(2):336–45. doi: 10.1097/SLA.0b013e31829291e9

20. Brouil J, Sherman M. Practice Guidelines Committee of AASLD: Management of hepatocellular carcinoma. Hepatol (Baltimore Md) (2005) 42(5):1208–36. doi: 10.1002/hep.20953

21. Zheng J, Seier K, Gonen M, Balachandran VP, Kingham TP, D’Angelica MI, et al. Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. Ann Surg Oncol (2017) 24(12):3760–14. doi: 10.1245/s10434-017-0660-7

22. Zhang W, Tan Y, Jiang L, Yan L, Yang J, Li B, et al. Prognostic nomogram for patients with non-B non-C hepatocellular carcinoma after curative liver resection. Int J Surg (London) (2017) 44:160–5. doi: 10.1016/j.ijsu.2017.06.041

23. Johnson PJ, Berhane S, Kagayabashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol Off J Am Soc Clin Oncol (2015) 33(6):550–8. doi: 10.1200/JCO.2014.57.9151

24. Wislez M, Rabbe J, Marchal M, Jullieron B, Crestani B, Mayaud C, et al. Hepatocyte growth factor production by neutrophils in bronchioalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res (2003) 63(6):1405–12.

25. Zhang XP, Wang K, Gao YZ, Wei XB, Lu CD, Chai ZT, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma. J Gastrointest Surg Off J Soc Surg Aliment (2013) 17(5):1077–83. doi: 10.1002/lias.11524

26. Mogensen UB, Iswaran H, Gerds TA. Evaluating Random Forests for Survival Analysis using Prediction Error Curves. J Stat Softw (2012) 50(11):1–23. doi: 10.18637/jss.v050.i11

27. European Association for the Study of the Liver and Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol (2018) 69 (1):182–236. doi: 10.1016/j.jhep.2018.03.019

28. Forman A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 30(3):61–74. doi: 10.1055/s-0030-1247133

29. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 56(4):908–43. doi: 10.1016/j.jhep.2011.12.001

30. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol Eur Soc Surg Oncol Br Assoc Surg Oncol (2008) 34(1):55–60. doi: 10.1016/j.ejso.2007.02.014

31. Overbø RM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res (2005) 65(19):8896–904. doi: 10.1158/0008-5427.CAN-05-1734
Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, et al. Neutrophils promote the malignant glioma phenotype through S100A4. *Clin Cancer Res an Off J Am Assoc Cancer Res* (2014) 20(1):187–98. doi: 10.1158/1078-0432.CCR-13-1279

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* (2004) 21(2):137–48. doi: 10.1016/j.immuni.2004.07.017

Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. *Radiat Oncol (London England)* (2010) 5:47. doi: 10.1186/1748-717X-5-47

Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol* (2014) 15(11):e493–503. doi: 10.1016/S1470-2045(14)70263-3

Zhang X-P, Liu Y-C, Chen Z-H, Sun J-X, Wang K, Chai Z-T, et al. Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis. *Ann Surg Oncol* (2019) 26(5):1465–73. doi: 10.1245/s10434-019-07223-z

Wang YY, Wang LJ, Xu D, Liu M, Wang HW, Wang K, et al. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. *HPB* (2019) 21(4):425–33. doi: 10.1016/j.hpb.2018.08.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.